Perspective from Allen C. Ho, MD, FACS
July 31, 2019
1 min read
Save

LCA10 trial of CRISPR genome editing treatment initiated

Perspective from Allen C. Ho, MD, FACS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A phase 1/2 clinical trial of AGN-151587, an experimental CRISPR-based genome editing medicine for the treatment of Leber congenital amaurosis 10, has been initiated by Allergan and Editas Medicine, according to a press release.

The open label Brilliance trial will evaluate the safety, tolerability and efficacy of AGN-151587 (EDIT-101) in approximately 18 patients in up to five cohorts across three dose levels, the release said.

Patients will receive a single subretinal injection in one eye following vitrectomy.

“Beginning patient enrollment in the AGN-151587 clinical trial with our partners at Editas is an important step toward our goal of developing a game-changing, transformative, CRISPR-based medicine for people with LCA10,” David Nicholson, PhD, chief research and development officer at Allergan, said in the release.